Apolipoprotein mimetics in cancer

Delk, Samuel; Chattopadhyay, Arnab; Escolà-Gil, Joan Carles; Fogelman, Alan M.; Reddy, Srinivasa T.

doi:10.1016/j.semcancer.2020.11.002

Cited by 31 publications

(23 citation statements)

References 110 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…vivo studies (24,(30)(31)(32)(33)(34)(35)(36)(37)(38). In the hematologic tumors, there was a relatively low level of HDL/ApoA-I in patients with acute lymphoblastic leukemia at diagnosis.…”

Section: Discussionmentioning

confidence: 99%

Prognostic and Therapeutic Value of Apolipoprotein A and a New Risk Scoring System Based on Apolipoprotein A and Adenosine Deaminase in Chronic Lymphocytic Leukemia

Yun

Sun

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

Lipid metabolism is related to lymphomagenesis, and is a novel therapeutic target in some hematologic tumors. Apolipoprotein A (ApoA), the major protein of high-density lipoprotein (HDL), plays a crucial role in lipid transportation and protecting against cardiovascular disease, and takes effect on anti-inflammation and anti-oxidation. It is correlated with the prognosis of some solid tumors. Yet, there is no investigation involving the role of ApoA plays in chronic lymphocytic leukemia (CLL). Our retrospective study focuses on the prognostic value of ApoA in CLL and its therapeutic potential for CLL patients. Herein, ApoA is a favorable independent prognostic factor for both overall survival (OS) and progression-free survival (PFS) of CLL patients. ApoA is negatively associated with β2-microglobulin (β2-MG) and advanced stage, which are poor prognostic factors in CLL. Age, Rai stage, ApoA, and adenosine deaminase (ADA) are included in a new risk scoring system named ARAA-score. It is capable of assessing OS and PFS of CLL patients. Furthermore, cell proliferation assays show that the ApoA-I mimetic L-4F can inhibit the proliferation of CLL cell lines and primary cells. In conclusion, ApoA is of prognostic value in CLL, and is a potential therapy for CLL patients. The ARAA-score may optimize the risk stratification of CLL patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic and Therapeutic Value of Apolipoprotein A and a New Risk Scoring System Based on Apolipoprotein A and Adenosine Deaminase in Chronic Lymphocytic Leukemia

Yun

Sun

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…A kind of transgenic tomato delivering Tg6F was reported to have promising effects in controlling metastatic colorectal cancer in experimental nude mice. 33 This may provide another therapeutic selection for improving NACRT response in patients with low levels of serum apoAI.…”

Section: Discussionmentioning

confidence: 99%

Serum Apolipoprotein A-I Predicts Response of Rectal Cancer to Neoadjuvant Chemoradiotherapy

Guo

Chen

Zeng

et al. 2021

CMAR

View full text Add to dashboard Cite

Background: Serum lipids have been reported as prognosticators for malignancies, including rectal cancer (RC). Yet, their value in predicting the response of RC to neoadjuvant chemoradiotherapy (NACRT) remains unknown. This study aimed to assess the predictive abilities of serum lipids for a bad response, and to build a serum lipid-based prediction model. Methods: In total, 751 patients diagnosed with stage cII-III RC and treated with NACRT plus surgery from January 2007 to August 2018 were retrospectively reviewed and randomly divided into two data sets, in a ratio of 1:1. Receiver operating characteristics (ROC) analysis was conducted in the development set to select possible predictors of bad NACRT response from pathoclinical factors, including serum lipids. Multivariate logistic regression was conducted to further determine independent predictors, which were then used to develop a prediction index (PI). Finally, the PI was verified in the validation set, through ROC analysis and chi-squared test. Results: Five independent predictors were identified: tumor length ≥4 cm, cT4 stage, carcinoembryonic antigen ≥5.0 ng/mL, irradiation with three-dimensional conformal radiotherapy technique, and apolipoprotein A-I ≤1.20 g/L. Each of them was assigned a number of points. In the validation set, the area under the curve of PI appeared as 0.642 (95% confidence interval 0.586-0.697). The sensitivity, specificity, positive and negative predictive values, and concordance were 72.3%, 52.3%, 63.8%, 61.9%, and 63.0%, respectively. Conclusion: Serum apolipoprotein A-I was found to correlate negatively with the RC response to NACRT. It could serve as a biomarker for guiding individualized treatment and a potential target for improving sensitivity to chemoradiation.

show abstract

“…Namely, since non-malignant tissue shows significantly lower expression of SR-B1 compared to malignant tissue, it is suggested that HDL particles can be used as drug delivery systems and can have beneficial effects not only on the restriction of tumor growth but also on reduction in chemotherapy-induced cytotoxicity [167]. In recent years, HDL-based nanoparticles, as therapeutic delivery systems, have been developed to target tumor cells by taking advantage of their unique property to overexpress SR-B1 [192].…”

Section: Possible Therapeutic Implicationsmentioning

confidence: 99%

“…With this in mind, Ye et al used L-4F to enhance binding between nanoparticles and tumor cells, and by this approach, a longer median survival rate was achieved [197]. Another interesting approach was using the 5A peptide in the synthesis of docetaxel (DTX)-loaded sHDL, which exhibited sustained drug release, high cytotoxicity directed toward MCF-7 breast cancer cells, and prolonged survival in mice [192].…”

Section: Possible Therapeutic Implicationsmentioning

confidence: 99%

Revealing the Role of High-Density Lipoprotein in Colorectal Cancer

Zeljković

Mihajlović

Gojković

et al. 2021

IJMS

View full text Add to dashboard Cite

Colorectal cancer (CRC) is a highly prevalent malignancy with multifactorial etiology, which includes metabolic alterations as contributors to disease development. Studies have shown that lipid status disorders are involved in colorectal carcinogenesis. In line with this, previous studies have also suggested that the serum high-density lipoprotein cholesterol (HDL-C) level decreases in patients with CRC, but more recently, the focus of investigations has shifted toward the exploration of qualitative properties of HDL in this malignancy. Herein, a comprehensive overview of available evidences regarding the putative role of HDL in CRC will be presented. We will analyze existing findings regarding alterations of HDL-C levels but also HDL particle structure and distribution in CRC. In addition, changes in HDL functionality in this malignancy will be discussed. Moreover, we will focus on the genetic regulation of HDL metabolism, as well as the involvement of HDL in disturbances of cholesterol trafficking in CRC. Finally, possible therapeutic implications related to HDL will be presented. Given the available evidence, future studies are needed to resolve all raised issues concerning the suggested protective role of HDL in CRC, its presumed function as a biomarker, and eventual therapeutic approaches based on HDL.

show abstract

Apolipoprotein mimetics in cancer

Cited by 31 publications

References 110 publications

Prognostic and Therapeutic Value of Apolipoprotein A and a New Risk Scoring System Based on Apolipoprotein A and Adenosine Deaminase in Chronic Lymphocytic Leukemia

Prognostic and Therapeutic Value of Apolipoprotein A and a New Risk Scoring System Based on Apolipoprotein A and Adenosine Deaminase in Chronic Lymphocytic Leukemia

Serum Apolipoprotein A-I Predicts Response of Rectal Cancer to Neoadjuvant Chemoradiotherapy

Revealing the Role of High-Density Lipoprotein in Colorectal Cancer

Contact Info

Product

Resources

About